ALNY - Alnylam Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
88.32
-0.36 (-0.41%)
As of 9:33AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close88.68
Open88.13
Bid86.65 x 900
Ask88.68 x 1100
Day's Range88.13 - 88.32
52 Week Range60.27 - 146.79
Volume2,142
Avg. Volume850,416
Market Cap9.389B
Beta (3Y Monthly)2.30
PE Ratio (TTM)N/A
EPS (TTM)-7.57
Earnings DateMay 1, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est120.67
Trade prices are not sourced from all markets
  • Alnylam's (ALNY) Impressive Pipeline Drives Share Price
    Zacks3 days ago

    Alnylam's (ALNY) Impressive Pipeline Drives Share Price

    Alnylam's (ALNY) share price increases on robust performance of pipeline candidates.

  • Markit9 days ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNYView full report here! Summary * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for ALNY with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold ALNY had net inflows of $3.63 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Alnylam Files Application for Hypertension Candidate in UK
    Zacks9 days ago

    Alnylam Files Application for Hypertension Candidate in UK

    Alnylam (ALNY) submits a CTA application to The Medicines and Healthcare products Regulatory Agency in the United Kingdom for ALN-AGT for the treatment of uncontrolled hypertension.

  • Business Wire10 days ago

    Alnylam Submits CTA Application for ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension in High Unmet Need Settings

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that the Company has submitted a clinical trial authorization (CTA) application to The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom to initiate a Phase 1 study of ALN-AGT, an investigational RNAi therapeutic targeting angiotensinogen (AGT) for the treatment of hypertension in high unmet need populations, including patients with resistant or refractory hypertension, chronic kidney disease or heart failure. The Company plans to initiate a Phase 1 study in mid-2019, upon obtaining MHRA approval. “We are excited to expand our efforts in the cardiovascular disease setting in pursuit of a novel approach to treat hypertension, particularly given that hypertensive disorders are the leading preventable cause of death in modern society.

  • Why Is Alnylam (ALNY) Up 3.1% Since Last Earnings Report?
    Zacks12 days ago

    Why Is Alnylam (ALNY) Up 3.1% Since Last Earnings Report?

    Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Business Wire14 days ago

    Alnylam to Webcast Presentation at Cowen & Company 39th Annual Health Care Conference

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Cowen & Company 39th Annual Health Care Conference on Wednesday, March 13, 2019 at 11:20 am ET at the Marriott Copley Place in Boston. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform.

  • Alnylam Stock Down Despite Positive Phase III Givosiran Data
    Zacks14 days ago

    Alnylam Stock Down Despite Positive Phase III Givosiran Data

    Alnylam (ALNY) reports positive phase III data on investigational candidate, givosiran. Despite the results, its shares slipped almost 4% on investors' concern regarding adverse events.

  • Could This Biotech Sacrifice A Buy Point On Drug Safety Questions?
    Investor's Business Daily15 days ago

    Could This Biotech Sacrifice A Buy Point On Drug Safety Questions?

    Alnylam Pharmaceuticals stock slipped Wednesday as investors questioned the safety of its rare-disease drug, dubbed givosiran, in a late-stage test of patients with acute hepatic porphyria.

  • Reuters15 days ago

    Side effects of Alnylam's gene-silencing drug raise concerns, shares slip

    Alnylam Pharmaceuticals Inc's late-stage trial data on its new gene silencing drug cast doubt on its safety, even as results revealed its effectiveness in treating a rare, painful disease. Alnylam said the drug, givosiran, met the main goal of reducing the yearly number of attacks in patients with acute intermittent porphyria (AIP) - a disease that affects the liver and causes debilitating attacks that render most disabled. Givosiran's efficacy profile looks robust but its safety profile is materially worse than expected, SVB Leerink analyst Mani Foroohar said in a note.

  • MarketWatch15 days ago

    Alnylam Pharmaceuticals stock down 7.5% after announcing results of Phase 3 givosiran trial

    Shares of Alnylam Pharmaceuticals Inc. fell 7.5% in premarket trade Wednesday after the company announced results of a Phase 3 study of givosiran, an RNA interference therapy for the treatment of acute hepatic porphyria, a family of rare genetic diseases that can cause potentially life-threatening attacks of severe abdominal pain, weakness and fatigue. The study met its primary endpoint -- reducing the yearly rate of porphyria attacks compared with placebo -- and hit five of nine secondary endpoints. But investors seemed spooked by the high percentage of serious adverse events reported by patients on givosiran compared with those on a placebo: 20.8% of those on givosiran reported serious adverse events compared to 8.7% of patients on placebo, though the difference in overall adverse events was not as stark, with 89.6% of patients on the drug reporting adverse events of any kind compared with 80.4% of patients on placebo. One patient discontinued treatment after seeing the amount of the liver enzyme alanine aminotransferase increase to more than eight times the normal number. Acute hepatic porphyria happens when a genetic defect leads to issues with one of the enzymes responsible for making heme in the liver. That causes a build-up of heme precursors, which are toxic to the body. Alnylam's givosiran targets an enzyme in the heme-making pathway called aminolevulinic acid synthase 1 (ALAS1). Alnylam said full study results will be presented in April and the company plans to submit a new drug application in mid-2019. Shares of Alnylam have gained 10.8% in the past 3 months, while the S&P 500 has gained 3.5%.

  • After trial success, Alnylam plans to seek FDA approval for 2nd drug
    American City Business Journals15 days ago

    After trial success, Alnylam plans to seek FDA approval for 2nd drug

    The company announced Wednesday that its drug givosiran met its primary endpoints in a Phase 3 trial.

  • Business Wire15 days ago

    Alnylam Reports Positive Topline Results from ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that the ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) in development for the treatment of acute hepatic porphyria (AHP), met its primary efficacy endpoint and the majority of secondary endpoints. Specifically, givosiran met the primary endpoint of reduction in the annualized rate of composite porphyria attacks relative to placebo (p less than 0.00000001) and achieved statistically significant results for five of nine secondary endpoints (p less than 0.0001), with a safety and tolerability profile that the Company believes is encouraging, especially in this high unmet disease.

  • Can This Biotech Puppy Run With the Big Dogs?
    Motley Fool17 days ago

    Can This Biotech Puppy Run With the Big Dogs?

    Pfizer and Alnylam have a fierce, young contender with a chance to catch up in a big way.

  • Medicines Company (MDCO) Q4 Loss Widens, Inclisiran in Focus
    Zacks21 days ago

    Medicines Company (MDCO) Q4 Loss Widens, Inclisiran in Focus

    The Medicines Company (MDCO) suffers a wider-than-expected loss in Q4. At the same time, the company fails to generate revenues.

  • Business Wire21 days ago

    Alnylam Announces Recipients of First Annual Advocacy for Impact Grants Program

    – Competitive Grants Program Recognizes New Projects that Impact the ATTR Amyloidosis and Acute Hepatic Porphyria Patient Communities –

  • FDA panel says Karyopharm's cancer drug shows 'significant toxicity'
    American City Business Journals24 days ago

    FDA panel says Karyopharm's cancer drug shows 'significant toxicity'

    The company's path forward is uncertain after FDA officials wrote in an advisory committee briefing document Friday that Karyopharm's drug was linked to "significant toxicity" and potentially lowered cancer patients' survival rates.

  • GuruFocus.comlast month

    Alnylam Pharmaceuticals Inc (ALNY) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Alnylam Pharmaceuticals Inc is a biopharmaceutical company. Warning! GuruFocus has detected 3 Warning Signs with ALNY. For the last quarter Alnylam Pharmaceuticals Inc reported a revenue of $21.0 million, compared with the revenue of $37.92 million during the same period a year ago.

  • Is Moderna a Buy?
    Motley Foollast month

    Is Moderna a Buy?

    The biggest-ever biotech IPO heralds enormous promise for a new class of medicines.

  • Alnylam Pharmaceuticals Is Launched and Ready for More
    Motley Foollast month

    Alnylam Pharmaceuticals Is Launched and Ready for More

    The biotech has launched its first drug, Onpattro, but don't forget about its pipeline of drugs to come.

  • GlobeNewswirelast month

    Detailed Research: Economic Perspectives on DXC Technology, AMC Networks, SunCoke Energy Partners, Alnylam Pharmaceuticals, Amtech, and Diamond Hill Investment Group — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of ALNY earnings conference call or presentation 7-Feb-19 9:30pm GMT

    Q4 2018 Alnylam Pharmaceuticals Inc Earnings Call

  • Benzingalast month

    The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs

    The following are top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 7.) Array Biopharma Inc (NASDAQ: ARRY ) Down In The Dumps (Biotech ...